The pharmacokinetics of moxalactam were studied in 86 normal adult male volunteers who received single or multiple doses intravenously or intramuscularly. The short absorption half-times and lag times indicate that the intramuscular dose is rapidly absorbed. The mean plasma half-life was 1.85 ± 0.24 h for intravenous doses and 2.24 ± 0.44 h for intramuscular doses. The mean renal clearances for intravenous doses were 0.052 and 0.067 liters/kg per h for intramuscular doses. Although moxalactam is eliminated primarily by the kidney, a chromatogram of the feces from volunteers who received multiple doses showed that it is also excreted as the parent compound into the feces via the biliary tract. The pharmacokinetic parameters of moxalactam when administered intravenously or intramuscularly in single and multiple doses clearly show that the kinetics of moxalactam are linear over the dosage ranges studied and are independent of dose.
The pharmacokinetics of moxalactam were studied in 86 normal adult male volunteers who received single or multiple doses intravenously or intramuscularly. The short absorption half-times and lag times indicate that the intramuscular dose is rapidly absorbed. The mean plasma half-life was 1.85 ± 0.24 h for intravenous doses and 2.24 ± 0.44 h for intramuscular doses. The mean renal clearances for intravenous doses were 0.052 and 0.067 liters/kg per h for intramuscular doses. Although moxalactam is eliminated primarily by the kidney, a chromatogram of the feces from volunteers who received multiple doses showed that it is also excreted as the parent compound into the feces via the biliary tract. The pharmacokinetic parameters of moxalactam when administered intravenously or intramuscularly in single and multiple doses clearly show that the kinetics of moxalactam are linear over the dosage ranges studied and are independent of dose.
Moxalactam is a new beta-lactam antibiotic with an expanded gram-negative spectrum of antibacterial activity (1, 7, 8, 18, 28, 31) . Pharmacokinetic studies have been performed in a limited number of normal volunteers given single intravenous infusions (2, 6, 13, 21, 22, 27, 32) and sirigle intramuscular doses (13, 22) . This study examines the pharmacokinetics of moxalactam administered to healthy volunteer subjects intravenously at single doses of 0.25 to 4 g and at multiple doses of up to 12 g daily and intramuscularly at single doses of 0.25 to 1 g and at multiple doses of up to 3 g daily. Preliminary results of this study have been reported (11) .
MATERIAULS AND METHODS Subjects. We used 86 healthy adult male volunteer subjects, between the ages of 23 and 60 years and weighing 56 to 98 kg (mean 74 kg). The volunteers signed written statements of informed consent to participate in the study. The volunteers were judged normal on the basis of a physical examination and clinical laboratory tests which included complete blood count, urinalysis, prothrombin time, partial thromboplastin time, serum glutamate pyruvate transaninase, serum glutamate oxalacetate transaminase, glucose, serum creatinine, and blood urea nitrogen. Subjects were instructed to take no other medication for 1 week before and during the study.
Design. Moxalactam was administered intravenously in 100 ml of 5% dextrose and water over a 20-min On days of blood and urine sampling, the subjects fasted until 1.5 h after the termination of the intravenous infusion or intramuscular injection. Heparinized venous blood samples for the assay of plasma concentrations of moxalactam were obtained at 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , and 12 h after the single-dose intravenous infusions were begun and 0, 0.5, 1, 2, 3, 4, 6 , and 8 h after the 8-h multiple-dose infusions were begun. Additional heparinized blood samples were collected at 10 and 12 h after the 12-h multiple-dose infusions. Heparinized venous blood samples for the determination of moxalactam in plasma were obtained at 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, and 8 h after each 8-h multiple-dose intramuscular injection. Additional heparinized blood samples were collected at 10 and 12 h after each single-dose and the every-12-h multiple-dose intramuscular injection.
Urine samples were collected at 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10, 10 to 12, and 12 to 24 h after single-dose treatments and at the last of the multiple-dose treatments. Just before drug administration, each subject emptied his bladder. This urine sample was used as a blank for the detection of microbiologically active substances.
Asays. As soon as plasma specimens were collected, they were iced and carried to the laboratory. They were immediately assayed microbiologically in triplicate with a standard agar well diffusion assay method (10) , trypticase soy agar (pH 7.4), and E. coli ATCC 4157 as the indicator organism. Concentrations of greater than 0.5 ,ug/ml could be detected by using this assay and the indicator organism. Urine samples were frozen at -20°C and assayed turbidometrically within 24 to 72 h after collection by using an Autoturb (Elanco Products Co.), E. coli ATCC 4157 as the indicator organism, and Penassay broth (Difco Laboratories; pH 6.6) (10). The standard curve was prepared in phosphate buffer (pH 6.6). Concentrations of 10, 5, 2, and 1 ,ug/ml were placed in a carousel and were then diluted. From 1 to 100 dilutions of the curve points were made, giving the assay a sensitivity of 1 pg/ml. All samples were run in quadruplicate. The turbidometric assay of moxalactam in urine has been shown by us to have a standard error of less than 3%. This assay allows the handling of more samples and is much faster than the diffusion assay.
The feces from volunteers who received moxalactam at doses of 2 g every 8 h for 28 doses were collected on the last dosing day. Immediately upon collection, the fecal samples were diluted with gelatin phosphate buffer at pH 7.0, homogenized with a Stomacher and centrifuged at 2,700 rpm (1,520 x g) for 20 min. A total of 5 ,zl of supernatant and 1 ,ug of the standard were spotted on a thin-layer cellulose-aluminum chromatography plate. The plate was developed by using a solvent system (methanol, 6 parts; npropanol, 2 parts; and water 1 part) (29) . The plate was air-dried and placed face down on an agar plate seeded with E. coli ATCC 4157. After 20 min, the plate was The distribution exponent a and the elimination exponent P are expressed in hours, and t is the time elapsed after the start of the intravenous infusion or intramuscular injection. In equation 2, the elimination intercept B and absorption intercept E are expressed in kilograms per liter. Ka is the absorption exponent multiplying t -t', where t' is the lag time. The initial estimates for A, B, a, P, E, and Ka were calculated by using program C-strip (24) . The other parameters are Vc, the volume of the central compartment, Vd,,, the apparent volume of distribution at steady state, Vd aea the apparent volume of distribution calculated from the area under the plasma concentration time curve; AUCO-., the area under the curve extrapolated to infinity, t1l2n, the plasma elimination half-life, and Clp and Cli, the plasma and renal clearances, respectively.
All of the above-mentioned parameters were calculated as suggested by Wagner (30) . The pharmacokinetic parameters in Tables 3 and 4 are dose and body weight invariant, and, in addition, parameters in Table 3 are corrected for the infusion time as suggested by Wagner (30) .
RESULTS

Peak plasma concentrations of moxalactam
ranged from 20 to 443 ,ug/ml after single intravenous doses of 0.25 to 4 g (Fig. 1) . Multiple intravenous infusions of 0.25, 0.5, 1, and 2 g were administered every 12 and 8 h for 10 days ( Fig. 2 and 3) , and multiple infusions of 3 and 4 g were given every 8 h for 7 doses (Fig. 4) . Peak plasma concentrations of moxalactam ranged from 20^Lg/ml after multiple doses of 0.25 g to 456 ,ug/ml after 4-g multiple doses on days that blood was sampled. Moxalactam concentrations after dose 1 of the 0.5 g every 12 h multiple doses are not shown in Fig. 2 because the volunteers were administered the incorrect dose. Peak plasma concentrations of moxalactam ranged from 10 to 27 ,ug/ml at 1 to 2 h after single intramuscular doses of 0.25 to 1 g, respectively (Fig. 5) . After multiple intramuscular doses of 0.25, 0.5, and 1 g were administered, peak plasma concentrations ranged from 6 to 35 ,ug/ml at 1 to 2 h ( Fig. 6 and 7) .
Of the administered moxalactam dose, 49 to 92% was recovered in the urine over a 24-h period after single intravenous doses and 55 to 65% in 24 h after single intramuscular doses (Table 1) . Urinary excretion was highest in the first 4 h after the start of the 20-min infusion or intramuscular injection. The 24-h urinary excretion was determined to be equivalent to the urinary excretion at infinity by the method of Newburger et al. (20) .
Fecal specimens were collected from subjects who received 2 g intravenously every 8 h for 28 doses. A chromatogram of the feces, collected on the last dosing day, showed that moxalactam is excreted as the parent compound into the feces via the biiary tract. 
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) l (Table 2) . When administered intravenously, moxalactam has a rapid distribution phase; therefore, the pharmacokinetic parameters of A and a show more variability from dose to dose, since these parameters are derived from a few points on the plasma concentration time curve and are most influenced by the correction for the infusion time.
Since Ka (2.60 h-1) in the intramuscular studies is similar to a (5.42 h-1) in the intravenous infuision studies, Ka could not be kinetically differentiated from a; therefore, all intramuscular data were fitted by using a single exponent for elimination and a single exponential for absorjption. The elimination rate constant (0.308 h-) for intramuscular doses was quite similar to that obtained after intravenous administration (0.376 h-1). The lag times used to fit the intramuscular data kinetically were very short (mean, 0.111 h) and in some subjects, it actually was zero. The short lag times and absorption half-times indicate that the intramuscular dose is rapidly absorbed.
The volume and clearance parameters after intramuscular administration can be corrected to the intravenous estimates by multiplying these parameters by the fraction absorbed (f = 0.8).
Since a large percentage of moxalactam is excreted as the parent drug in the urine, it is reasonable to assume that moxalactam does not The mean pharmacokinetic parameters of moxalactam when administered intravenously and intramuscularly are summarized in Tables 2  and 3 , respectively, and represent a combination of data derived from each single dose and the first dose of each multiple-dose treatment. Data from the other multiple intravenous or intramuscular doses were not included because the fit was kinetically identical to the single-dose data.
Intravenous data indicates that there is a biexponential decay of moxalactam with a disposition or a-phase and an elimination or 1-phase which is logarithmically linear and occurs within 1.5 h postinfusion. The pharmacokinetic parameters of a, B, AUCO_c, Vds, Vd., Clp, and Clr after intravenous administration are consistent from dose to dose, which clearly indicates that the kinetics of moxalactam when given intravenously are linear over the dosage ranges studied and are independent of dose SD a concentration curve, extrapolated to infinity, increases proportionately with increases in dose (in milligrams per kilogram). This AUC0_. is not corrected for dose and weight of the subject. No significant adverse reactions were observed, except that a few subjects who received multiple intravenous doses experienced brief periods of diarrhea characterized by an average of one to three very loose to watery stools per day for 1 to 5 days, but the diarrhea resolved during drug administration. The diarrhea did not appear to be dose related. In one subject, the course of the diarrhea was longer, lasting 8 days; therefore, a sigmoidoscopy was performed and revealed no evidence of colitis or pathological abnormalities except for a sessile polyp. Two volunteers who received 4 g every 8 h for seven doses experienced disulfuram-like reactions. These reactions occurred after the subjects ingested alcohol 30 to 48 h after the last dose of moxalactam. A few subjects had minimal elevations in serum glutamate pyruvate transaminase and serum glutamate oxalacetate transaminase at the end of the study. A direct relationship between these elevations and moxalactam could not be established.
DISCUSSION
In this study, the plasma data for moxalactam were fitted kinetically by using model-independent methods as described by Wagner (30) . Unlike cephalothin, cefamandole, cefoxitin, and cefotaxime, which have short plasma half-lives ranging from approximately 0.7 to 1.2 h when administered intravenously or intramuscularly (3, 9, 17, 32) , our data show that moxalactam has a longer plasma half-life (1.85 ± 0.24 h for intravenous doses and 2.24 ± 0.44 h for intramuscular doses) which allows an 8-or 12-h dosing schedule to be used in a clinical setting. Others have reported serum half-lives for moxalactam ranging from 2.3 to 3.5 h after intravenous administration (2, 6, 13, 21, 22, 27, 32) and 2.3 to 2.5 h after intramuscular administration (2, 27).
A least-square regression analysis of all individual single-and multiple-dose data combined shows a linear increase in the amount absorbed with an increase in dose. The reciprocal of the slope in Fig. 8 and 9 is equivalent to the mean plasma clearance to moxalactam as calculated from the pharmacokinetic parameters. Analysis of the pharmacokinetic data for intramuscular and intravenous doses also shows that the kinetics are linear over the dosage ranges studied and are independent of dose.
Moxalactam is eliminated primarily by the kidney. As calculated from our data, renal clearance of moxalactam for a 70-kg man is approxi- (17, 23, 27) , but lower than that reported for other cephalosporin antibiotics, including cefotaxime (9, 17, 26) , and higher than that reported for cefoperazone (26) . Studies show that probenecid does not affect the pharmacokinetics of moxalactam (5, 25) ; therefore, this antibiotic appears to be eliminated primarily by glomerular filtration and not by tubular secretion. Moxalactam is also eliminated by a nonrenal route as shown in our study and by others (14) . Plasma clearance of moxalactam ranges from 87 to 99 ml/min for intravenous doses and 113 to 118 ml/ min (uncorrected for ff) for intramuscular doses. The plasma clearance is slightly higher than that observed for cefazolin (17, 23, 27) and cefoperazone (26) but lower than that seen with other cephalosporin antibiotics, including cefotaxime (9, 17, 23) . The apparent volume of distribution is consistent with the apparent volume of distribution for other cephalosporins (23) . Other investigators (2, 6, 13, 21, 22, 27, 32) have studied the pharmacokinetics of moxalac- tam in normal healthy volunteers, and the results of their studies agree with our findings.
Disulfuram-like reactions with moxalactam (19) and cefoperazone (12, 15) 22, 1982 
